REG - Verici Dx PLC - Result of AGM

Verici DxAnnouncement

25/06/2024 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240625:nRSY8191Ta&default-theme=true

RNS Number : 8191T  Verici Dx PLC  25 June 2024

Verici Dx plc

("Verici Dx" or the "Company")

 

Result of AGM and voting results

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that at the Annual General Meeting ("AGM") held
earlier today, all resolutions were duly passed.

 

The voting results of the AGM were as follows:

 

             In Favour           Against          Withheld
 Resolution  Votes        %      Votes      %     Votes
 1           109,919,167  97.96  2,287,678  2.04  76
 2           112,096,318  99.90  110,603    0.10  0
 3           112,205,310  99.99  1,611      0.01  0
 4           112,081,736  99.89  125,185    0.11  0
 5           112,085,956  99.89  120,965    0.11  0
 6           111,792,090  99.63  414,740    0.37  91
 7           112,203,528  99.99  3,233      0.01  160
 8           112,192,472  99.99  14,289     0.01  160
 9           112,154,800  99.95  51,921     0.05  200

 

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     investors@vericidx.com
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Aubrey Powell / Sam Butcher

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBDGDLRDDDGSU